Biomarker-directed therapy in black and white men with metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Hwang, Clara
Henderson, Nicholas
Cackowski, Frank Cameron
Pilling, Amanda
Jang, Albert
Rothstein, Shoshana
Labriola, Matthew
Park, Joseph J.
Ghose, Alyssa
Bilen, Mehmet Asim
Kilari, Deepak
Tripathi, Abhishek
Garje, Rohan
Koshkin, Vadim S.
Schweizer, Michael Thomas
Armstrong, Andrew J.
Mckay, Rana R.
Dorff, Tanya B.
Alva, Ajjai Shivaram
Barata, Pedro C.
机构：
[1] Henry Ford Hlth Syst, Detroit, MI USA
[2] Univ Michigan, Dept Biostat, Ann Arbor, MI USA
[3] Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[4] Tulane Univ, Sch Med, New Orleans, LA USA
[5] Duke Univ, Div Med Oncol, Durham, NC USA
[6] Univ Michigan, Dept Med, Div Hematol & Oncol, Ann Arbor, MI USA
[7] Univ Michigan, Ann Arbor, MI USA
[8] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA USA
[9] Med Coll Wisconsin, Froedtert Canc Ctr, Dept Med, Milwaukee, WI USA
[10] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA
[11] Univ Iowa, Div Hematol Oncol, Dept Internal Med, Iowa City, IA USA
[12] Univ Calif San Francisco, San Francisco, CA USA
[13] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA USA
[14] Duke Univ, Sch Med, Duke Canc Inst, Ctr Prostate & Urol Canc, Durham, NC USA
[15] Univ Calif San Diego Hlth, La Jolla, CA USA
[16] City Hope Comprehens Canc Ctr, Duarte, CA USA
[17] Univ Michigan, Rogel Comprehens Canc Ctr, Ann Arbor, MI USA
[18] Tulane Univ, Sch Med, New Orleans, LA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5013
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Treatment outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) and cardiovascular disorders or diabetes: The Prostate Cancer Registry.
    Lumen, Nicolaas
    Chowdhury, Simon
    Birtle, Alison J.
    Bjartell, Anders
    Costa, Luis
    Feyerabend, Susan
    Galli, Luca
    Kalinka-Warzocha, Ewa
    Kramer, Gero
    Maroto, Pablo
    Matveev, Vsevolod B.
    Paiss, Thomas
    Pisconti, Salvatore
    Spaeth, Dominique
    Veiga, Francisco Gomez
    Antoni, Laurent
    Klumper, Edwin
    Wapenaar, Robert
    Thoret-Bauchet, Florence
    Lee, Emma
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [42] Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England
    Ng, Kenrick
    Wilson, Peter
    Mutsvangwa, Katherine
    Hounsome, Luke
    Shamash, Jonathan
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (03) : 718 - 724
  • [43] Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England
    Kenrick Ng
    Peter Wilson
    Katherine Mutsvangwa
    Luke Hounsome
    Jonathan Shamash
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 718 - 724
  • [44] Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC).
    Conteduca, Vincenza
    Wetterskog, Daniel
    Scarpi, Emanuela
    Romanel, Alessandro
    Gurioli, Giorgia
    Jayaram, Anuradha
    Lolli, Cristian
    Schepisi, Giuseppe
    Casadei, Chiara
    Menna, Cecilia
    Wingate, Anna
    Demichelis, Francesca
    De Giorgi, Ugo
    Attard, Gerhardt
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] Combining functional imaging with circulating biomarker analysis to improve prognostication of metastatic castration-resistant prostate cancer (mCRPC)
    Conteduca, V.
    Salvi, S.
    Caroli, P.
    Scarpi, E.
    Schepisi, G.
    Lolli, C.
    Wetterskog, D.
    Burgio, S. L.
    Menna, C.
    Casadio, V.
    Matteucci, F.
    Paganelli, G.
    Attard, G.
    De Giorgi, U.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] Metastatic castration-resistant prostate cancer
    Henriques, Vanessa
    Wenzel, Mike
    Demes, Melanie-Christin
    Koellermann, Jens
    PATHOLOGE, 2021, 42 (04): : 431 - 438
  • [47] Impact of number of lines of therapy following docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC).
    Sonpavde, Guru
    Bhor, Menaka
    Hennessy, Daniel
    Bhowmik, Debajyoti
    Shen, Liji
    Schnadig, Ian D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [48] Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer
    Michael T. Schweizer
    Roman Gulati
    Todd Yezefski
    Heather H. Cheng
    Elahe Mostaghel
    Michael C. Haffner
    Radhika A. Patel
    Navonil De Sarkar
    Gavin Ha
    Ruth Dumpit
    Brianna Woo
    Aaron Lin
    Patrick Panlasigui
    Nerina McDonald
    Michael Lai
    Katie Nega
    Jeannette Hammond
    Petros Grivas
    Andrew Hsieh
    Bruce Montgomery
    Peter S. Nelson
    Evan Y. Yu
    Prostate Cancer and Prostatic Diseases, 2023, 26 : 194 - 200
  • [49] Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC).
    Pond, Gregory Russell
    Armstrong, Andrew J.
    Wood, Brian A.
    Leopold, Lance Howard
    Galsky, Matt D.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [50] Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer
    Schweizer, Michael T.
    Gulati, Roman
    Yezefski, Todd
    Cheng, Heather H.
    Mostaghel, Elahe
    Haffner, Michael C.
    Patel, Radhika A.
    De Sarkar, Navonil
    Ha, Gavin
    Dumpit, Ruth
    Woo, Brianna
    Lin, Aaron
    Panlasigui, Patrick
    McDonald, Nerina
    Lai, Michael
    Nega, Katie
    Hammond, Jeannette
    Grivas, Petros
    Hsieh, Andrew
    Montgomery, Bruce
    Nelson, Peter S.
    Yu, Evan Y.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2023, 26 (01) : 194 - 200
12345